EUVIMEDEUVIMED entdecken
Crossref

Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease

Tatiana R Rosenblatt, Carolina A Chiou, Michael K Yoon, Nahyoung Grace Lee, Natalie Wolkow, Suzanne K Freitag

British Journal of Ophthalmology · 2025

DOI: 10.1136/bjo-2024-325527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Ophthalmology, 2025. Verfasst von Tatiana R Rosenblatt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA trosenblatt@meei.harvard.edu. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Exophthalmos, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prior studies of teprotumumab for thyroid eye disease report proptosis reduction in millimetres, which does not fully capture teprotumumab’s clinical effect since a given number of millimetres change can be of variable impact depending on patients’ degree of pre-treatment proptosis. In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2–40.5%) of their pre-treatment proptosis, or 3.3 mm (range 0.5–10.0 mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab’s clinical impact.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyExophthalmosAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesFemaleMaleMiddle AgedAdultAgedTreatment OutcomeYoung AdultAged, 80 and over

Stichwörter der Autor:innen

CosmesisEye LidsInflammationOrbitTreatment Medical

Substanzen

Antibodies, Monoclonal, Humanizedteprotumumab

Autor:innen und Institutionen

  • Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA trosenblatt@meei.harvard.edu.
  • Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.

Zitieren

APA

Rosenblatt, T. R., Chiou, C. A., Yoon, M. K., Lee, N. G., Wolkow, N., & Freitag, S. K. (2025). Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease. British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2024-325527

Vancouver

Rosenblatt TR, Chiou CA, Yoon MK, Lee NG, Wolkow N, Freitag SK. Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease. British Journal of Ophthalmology. 2025. doi:10.1136/bjo-2024-325527

BibTeX
@article{Rosenblatt2025,
  author = {Rosenblatt, Tatiana R and Chiou, Carolina A and Yoon, Michael K and Lee, Nahyoung Grace and Wolkow, Natalie and Freitag, Suzanne K},
  title = {Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease},
  journal = {British Journal of Ophthalmology},
  year = {2025},
  doi = {10.1136/bjo-2024-325527}
}
Kostenlos starten →